<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38324">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01683422</url>
  </required_header>
  <id_info>
    <org_study_id>5110324</org_study_id>
    <nct_id>NCT01683422</nct_id>
  </id_info>
  <brief_title>Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current trial will provide important data on the recurrence rates and patterns of
      failure using state of the art target agent, chemotherapy and proton beam technology for
      patients with Locally Advanced Pancreatic Cancer (LAPC). A median survival of 10 months or
      greater would be considered evidence of a regimen potentially worthy of further study as a
      new treatment paradigm in one arm in a future phase III trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine the one-year survival rate</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the frequency of serious adverse events</measure>
    <time_frame>Ongoing</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Proton Radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton, Gemcitabine, Erlotinib, Capecitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.
Post-proton chemotherapy:  To be started in 4 to 6 weeks after completion of proton chemotherapy.  Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days.  The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles.</description>
    <arm_group_label>Proton Radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiation</intervention_name>
    <arm_group_label>Proton Radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed unresectable non-metastatic adenocarcinoma
             of the pancreas

          -  AJCC stage I-III with unresectable or borderline unresectable disease as defined by
             NCCN guidelines

          -  Radiological resectability is defined by the following criteria on abdominal imaging:

               1. No evidence of tumor extension to the celiac axis, hepatic artery or superior
                  mesenteric artery.

               2. No evidence of tumor encasement or occlusion of the superior mesenteric vein
                  (SMV) or the SMV/portal vein confluence

               3. No evidence of visceral or peritoneal metastases

          -  Borderline and Unresectable cases would be defined as those that do not meet the
             criteria in section and also show no evidence of distant metastatic or
             intraperitoneal disease.

          -  Eastern Cooperative Oncology Group performance status of ≤ 2

          -  Age &gt; 18 years

          -  Adequate hematologic reserve, hepatic reserve and renal function

          -  WBC &gt; 2,000 cells/mm3

          -  ANC &gt; 1,500 cells/mm3

          -  Platelets &gt; 100,000 cells/mm3

          -  Serum bilirubin ≤ 2.5 mg/dL

          -  Serum creatinine ≤ 2 x upper limit of normal (ULN), or creatinine clearance (Ccr) ≥
             30ml/min

          -  ALT &lt; 3 times ULN

          -  AST &lt; 3 times ULN

          -  Albumin &gt; 3.2 g/dl

          -  Patient must sign study-specific informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary Yang, MD</last_name>
    <phone>909-558-4280</phone>
    <email>gyang@llu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First Call: Proton Referral RN Backup: Sandi Teichman</last_name>
    <phone>1 800 776-8667</phone>
    <email>scteichm@llu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Yang, MD</last_name>
      <phone>909-558-4280</phone>
      <email>gyang@llu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Proton Referral</last_name>
      <phone>1 800 496-4966</phone>
    </contact_backup>
    <investigator>
      <last_name>Gary Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>February 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Gary Yang, MD</investigator_full_name>
    <investigator_title>MD, Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
